Thus, the reported benefits of GLP1-ras and SGLT-2 inhibitors on stroke, heart failure, and kidney disease are particularly desirable in African Americans with diabetes and need to be demonstrated definitively in that population [148]. This evidence concerns the gene SLC5A2 and diabetes mellitus.